Regulatory Acceptance of Alternative Methods in the Development and Approval of Pharmaceuticals.
Animal studies may be carried out to support first administration of a new medicinal product to either humans or the target animal species, or before performing clinical trials in even larger populations, or before marketing authorisation, or to control quality during production. Ethical and animal welfare considerations require that animal use is limited as much as possible. Directive 2010/63/EU on the protection of animals used for scientific purposes unambiguously fosters the application of the principle of the 3Rs when considering the choice of methods to be used.As such, today, the 3Rs are embedded in the relevant regulatory guidance both at the European (European Medicines Agency (EMA)) and (Veterinary) International Conference on Harmonization ((V)ICH) levels. With respect to non-clinical testing requirements for human medicinal products, reduction and replacement of animal testing has been achieved by the regulatory acceptance of new in vitro methods, either as pivotal, supportive or exploratory mechanistic studies. Whilst replacement of animal studies remains the ultimate goal, approaches aimed at reducing or refining animal studies have also been routinely implemented in regulatory guidelines, where applicable. The chapter provides an overview of the implementation of 3Rs in the drafting of non-clinical testing guidelines for human medicinal products at the level of the ICH. In addition, the revision of the ICH S2 guideline on genotoxicity testing and data interpretation for pharmaceuticals intended for human use is discussed as a case study.In October 2010, the EMA established a Joint ad hoc Expert Group (JEG 3Rs) with the mandate to improve and foster the application of 3Rs principles to the regulatory testing of medicinal products throughout their lifecycle. As such, a Guideline on regulatory acceptance of 3R testing approaches was drafted that defines regulatory acceptance and provides guidance on the scientific and technical criteria for regulatory acceptance of 3R testing approaches, including a process for collection of real-life data (safe harbour). Pathways for regulatory acceptance of 3R testing approaches are depicted and a new procedure for submission and evaluation of a proposal for regulatory acceptance of 3R testing approaches is described.
Division Evaluators, DG PRE Authorisation, Federal Agency for Medicines and Health Products (FAMHP), Victor Hortaplace 40/40, Brussels, 1060, Belgium. sonja.beken@fagg-afmps.be.
Sonja
S
Beken
Federal Institute for Drugs and Medical Devices (BfArM), Kurt-Georg-Kiesinger Allee 3, Bonn, 53175, Germany.
Peter
P
Kasper
Pharmacology, Toxicology and Biotechnology Department, Medicines Evaluation Board (MEB), Graadt van Roggenweg 500, 3531, AH, Utrecht, The Netherlands.
Jan-Willem
JW
van der Laan
D000826:Animal Testing Alternatives / Q000379:methods*; D000818:Animals; D015197:Carcinogenicity Tests / Q000379:methods; D055808:Drug Discovery; D017408:Guidelines as Topic; D006801:Humans; D009152:Mutagenicity Tests / Q000379:methods; D012098:Reproduction / Q000187:drug effects; D018675:Toxicity Tests / Q000379:methods*; D066007:Toxicokinetics
EMA; Genotoxicity; ICH; JEG 3Rs; Non-clinical; Pharmaceuticals; Reduction; Refinement; Regulatory testing; Replacement